tyrosine has been researched along with incretins in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chepurny, OG; Collier, JJ; Cooney, RN; Holz, GG; Leech, CA; Meng, Q; Molnar, ME; Pruekprasert, N | 1 |
| Andersson, O; Charbord, J; Chu, L; Dirice, E; Kulkarni, RN; Liu, KC; Mattsson, CL; Miskelly, MG; Teinturier, R; Terasaki, M; Wierup, N; Zhou, Q | 1 |
2 other study(ies) available for tyrosine and incretins
| Article | Year |
|---|---|
The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Humans; Incretins; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Nicotinic Agonists; Pyridines; Sitagliptin Phosphate; Tyrosine | 2022 |
In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Discovery; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Incretins; Mice; Tyrosine; Zebrafish | 2022 |